Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020-04-22
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01FX18
|
| gptkbp:chemicalFormula |
C6468H9956N1716O2016S44
|
| gptkbp:contains |
gptkb:SN-38
|
| gptkbp:developedBy |
gptkb:Immunomedics
|
| gptkbp:EMAApprovalDate |
2021-11-22
|
| gptkbp:firstBook |
yes
|
| gptkbp:form |
lyophilized powder for solution
|
| gptkbp:genericName |
gptkb:sacituzumab_govitecan
|
| gptkbp:halfLife |
16-19 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Trodelvy
|
| gptkbp:indication |
gptkb:triple-negative_breast_cancer
urothelial cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Gilead_Sciences
|
| gptkbp:mechanismOfAction |
gptkb:monoclonal_antibody
|
| gptkbp:orphanDrugStatus |
yes
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
nausea vomiting diarrhea fatigue alopecia rash neutropenia decreased appetite |
| gptkbp:target |
gptkb:Trop-2
|
| gptkbp:bfsParent |
gptkb:Immunomedics
|
| gptkbp:bfsLayer |
6
|